OncRef
Skip to newsletter content
|
SCLCJune 2026
0:00 / 2:56
Small Cell Lung Cancer — Monthly Compass
Jun 01–30, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
small cell lung cancer updates
Key Highlights
Key Highlights
  • Important Drug Publication Updates
    • ADRIATIC patient‑reported outcomes published in June 2026 reinforced the clinical value of consolidation durvalumab after cCRT in limited‑stage SCLC and provided data to support tolerability and payer value considerations in real‑world adoption.
  • Key Clinical Development Updates
    • Merck’s ifinatamab deruxtecan BLA for previously treated ES‑SCLC is under FDA Priority Review with an October 10, 2026 PDUFA date, targeting initial U.S. approval in ES‑SCLC with ongoing registrational plans and exploration of combinations including gocatamig.
    • Zai Lab received EMA Orphan Drug Designation for its DLL3‑targeting ADC zocilurtatug pelitecan following FDA Fast Track in May 2026 and plans three registration‑enabling studies across SCLC (second‑/first‑line) and epNEC by end‑2026, while Genprex’s Acclaim‑3 (REQORSA + atezolizumab maintenance) holds FDA Fast Track and Orphan Drug designations with a Phase 2 expansion ongoing and interim analysis timing set.
  • Important Clinical Trial Publications
    • Jazz announced top‑line Phase 3 LAGOON results for lurbinectedin in second‑line metastatic SCLC that did not meet the primary endpoint and shared the data with FDA to discuss next steps regarding post‑marketing requirements for the second‑line indication.
  • Key Conference Updates
    • ASCO 2026 highlighted intracranial efficacy of the DLL3×CD3 T‑cell engager tarlatamab versus chemotherapy in post‑hoc DeLLphi‑304 analyses, supporting its differentiated role in 2L+ ES‑SCLC including patients with baseline brain metastases and driving real‑world uptake.
    • The phase III LBA8005 program evaluating first‑line platinum/etoposide plus durvalumab with concurrent thoracic radiotherapy in ES‑SCLC signaled a move toward definitive thoracic control beyond chemo‑immunotherapy alone for fit patients in multidisciplinary settings.
  • Emerging Themes & Macro-Trends
    • Sponsors are prioritizing CNS‑specific endpoints and potential labeling for DLL3 agents, integrating RT‑IO workflows in first‑line ES‑SCLC, and accelerating SCLC‑focused ADC programs with biomarker selection and pragmatic toxicity management.
    • The antigen landscape in SCLC (B7‑H3, TROP2, DLL3, SEZ6) is enabling expansion of ADC strategies that may offer off‑the‑shelf options after chemo‑immunotherapy.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-06-01 and 2026-06-30 about small cell lung cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Merck reported that the BLA for ifinatamab deruxtecan (I-DXd) in previously treated extensive-stage SCLC is under FDA Priority Review with a PDUFA target action date of October 10, 2026; the ASCO 2026 investor presentation (updated June 9) highlights I-DXd’s initial U.S. approval objective in ES-SCLC and ongoing registrational plans. The company also notes exploration of combinations (e.g., with gocatamig) and reiterates the high unmet need in SCLC. ¹ (s21.q4cdn.com) (read more)
  • Jazz Pharmaceuticals announced top-line Phase 3 LAGOON results for Zepzelca (lurbinectedin) in second-line metastatic SCLC and said it has shared the data with FDA to discuss next steps regarding post-marketing requirements for the second-line indication. The release reiterates Zepzelca’s regulatory status in the U.S.: accelerated approval in June 2020 for 2L SCLC and full approval in October 2025 for first-line maintenance with atezolizumab. ² (investor.jazzpharma.com) (read more)
  • Media coverage the same day reported that Jazz plans FDA discussions on post‑marketing requirements for Zepzelca’s second-line indication following the LAGOON miss, emphasizing that first‑line maintenance approval remains intact. The article summarizes the trial outcome and the company’s planned regulatory engagement with FDA. ³ (americanpharmaceuticalreview.com) (read more)
  • Additional coverage on June 15 noted Jazz’s intent to review with FDA the implications for Zepzelca’s second‑line post‑marketing requirements and future regulatory pathway after LAGOON did not meet its primary endpoint. Shares declined on the news, but the piece underscores ongoing FDA interactions tied to the accelerated approval context. ⁴ (zacks.com) (read more)
  • Zai Lab announced EMA Orphan Drug Designation for its DLL3‑targeting ADC zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas and stated this closely follows FDA Fast Track designation in May 2026. The company outlined plans to initiate three registration‑enabling studies by end‑2026 across SCLC (second‑/first‑line) and epNEC, signaling planned FDA‑oriented development paths for SCLC. ⁵ (ir.zailaboratory.com) (read more)
  • Genprex filed a June 30 Form 8‑K noting its Acclaim‑3 study (REQORSA + atezolizumab maintenance) in ES‑SCLC has FDA Fast Track designation and FDA Orphan Drug Designation. The update confirms ongoing Phase 2 expansion and sets expectations for interim analysis timing, reinforcing the program’s active FDA‑recognized development status. ⁶ (sec.gov) (read more)
Conference
Major Conference Updates
Conference Information
  • 2026 ASCO Annual Meeting; Chicago, Illinois (McCormick Place); May 29–June 2, 2026.
  • SCLC highlights centered on DLL3-directed T‑cell engagers with CNS activity, immuno‑radiotherapy intensification, consolidation/peri‑CRT PD‑L1 strategies, and early signals of ADC expansion into SCLC.
  • Theme 1: DLL3 T‑Cell Engagers Show Intracranial Activity and Real‑World Uptake
    • Significance: Positions tarlatamab as a differentiated 2L+ option addressing a high‑need subgroup—patients with baseline brain metastases—while supporting broader, real‑world adoption. (read more)
    • Mechanism insights / clinical impact: DLL3×CD3 engagement drives T‑cell–mediated tumor lysis; post‑hoc DeLLphi‑304 analysis reported intracranial efficacy versus chemotherapy, aligning with clinician discussions at ASCO 2026. (read more)
    • Patient populations affected: ES‑SCLC after platinum‑based therapy, including those with treated/stable brain metastases and older adults (age‑stratified outcomes assessed). (read more)
  • Theme 2: Concurrent Chemo‑Immuno‑Radiotherapy in ES‑SCLC (Tri‑Modality)
    • Significance: A phase III program evaluating platinum/etoposide + durvalumab with concurrent thoracic RT (LBA8005) signals a shift toward definitive thoracic control in the first‑line extensive‑stage setting. (read more)
    • Mechanism insights / clinical impact: Radiotherapy may enhance antigen release and immune priming; expert commentary underscored the potential to improve thoracic disease control beyond chemo‑IO alone. (read more)
    • Patient populations affected: Fit, first‑line ES‑SCLC patients where integrated RT is feasible within multidisciplinary programs. (read more)
  • Theme 3: Consolidation and Peri‑CRT PD‑L1 Strategies in LS‑SCLC
    • Significance: ADRIATIC patient‑reported outcomes (PROs) and new peri‑CRT designs (CONCUR) reinforce consolidation durvalumab’s clinical value and test earlier sequencing to eradicate micrometastatic disease. (read more)
    • Mechanism insights / clinical impact: Post‑cCRT PD‑L1 blockade aims to sustain immune surveillance; PROs inform tolerability and payer value discussions in real‑world adoption. (read more)
    • Patient populations affected: Unresectable stage I–III (LS‑SCLC) completing concurrent chemoradiation; global applicability with site‑specific RT standards. (read more)
  • Theme 4: ADC Momentum Targeting B7‑H3 in Relapsed SCLC
    • Significance: Multiple June‑2026 presentations spotlight B7‑H3 ADCs, broadening post‑IO options and competing with DLL3 agents on convenience and tumor‑antigen breadth. (read more)
    • Mechanism insights / clinical impact: B7‑H3–targeted ADCs (e.g., SYS6043; 7MW3711) leverage topo‑I payloads; Education Book synthesis highlights SCLC expression of B7‑H3/TROP2/DLL3/SEZ6 as druggable antigen landscape. (read more)
    • Patient populations affected: Pretreated ES‑SCLC (2L+), including those progressing after chemo‑IO where ADCs may offer off‑the‑shelf alternatives. (read more)
  • Significance
    • Expected clinical or translational readouts: Mature outcomes and CNS‑focused analyses from DeLLphi‑304; updated survival/RT‑specific endpoints from LBA8005; peri‑CRT feasibility signals (CONCUR); expansion of B7‑H3 ADC datasets. (read more)
    • Regulatory or policy implications: ADRIATIC PROs strengthen health‑technology assessments and maintenance‑IO coverage arguments in LS‑SCLC. (read more)
    • Potential shifts in standard of care: If tri‑modality benefits are confirmed, first‑line ES‑SCLC could evolve from chemo‑IO to chemo‑IO‑TRT for appropriate patients; DLL3 TCEs may become preferred in 2L with brain metastases. (ascopubs.org) (read more)
    • Strategic implications: Prioritize CNS‑specific endpoints/labeling for DLL3 agents; invest in RT‑IO workflow integration; accelerate SCLC‑enriched ADC programs with biomarker selection and pragmatic toxicity management. (read more)
Publications Related to Approved Drugs
Unknown Drug
There are no new publication updates during the 2026-06-01 to 2026-06-30 for small cell lung cancer.
New Publications Related to Drugs in Clinical Trial Development
Phase 3
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. Long-term follow-up from the RATIONALE-312 trial confirms that first-line tislelizumab plus chemotherapy provides a sustained and clinically meaningful overall survival benefit for patients with extensive-stage SCLC compared to chemotherapy alone. With a median follow-up of nearly 40 months, the OS benefit was consistent across PD-L1 expression subgroups, reinforcing this combination as a standard of care with a tolerable long-term safety profile. ()
Phase 1
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer. In a phase I dose-expansion study for relapsed/refractory SCLC, the AURKB inhibitor AZD2811 demonstrated modest antitumor activity (ORR 4.8%, stable disease 47.6%) with manageable hematologic toxicity. Importantly, the study highlights the potential of ctDNA as a prognostic biomarker and an early indicator of treatment response and progression, suggesting a personalized surveillance strategy could enhance disease monitoring in SCLC. ()
Phase 1
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. This first-in-human phase 1 study of lomvastomig, a PD-1-TIM-3 bispecific antibody, established a recommended phase 2 dose of 2,100 mg Q2W with a manageable safety profile in patients with advanced solid tumors, including a cohort of CPI-naïve SCLC patients. While overall clinical activity was limited in CPI-experienced patients, the study provides foundational safety and pharmacokinetic data for this novel dual checkpoint inhibitor. ()
Phase 2
Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study. This phase II, single-arm study protocol outlines a multimodal strategy for untreated extensive-stage SCLC, combining quadruple induction therapy (benmelstobart, anlotinib, platinum-etoposide) with consolidation thoracic radiotherapy. The trial aims to evaluate the safety and efficacy of this comprehensive approach, potentially establishing a new first-line treatment paradigm that integrates chemo-immuno-antiangiogenic therapy with local radiation control. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in small cell lung cancer updated from 2026-06-01 to 2026-06-30:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation1-----1
Not Yet Recruiting411424227
Recruiting31182345182
Available-------
Approved for Marketing-------
Active, Not Recruiting10726-12-55
Completed-12-2-5
Total4627656233170
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
BG-68501, BGB-43395, Fulvestrant NCT06257264 ACTIVE_NOT_RECRUITING A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors 2026-08-31
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Cisplatin, Paclitaxel, Pemetrexed, : Relatlimab, : Nivolumab, Nab-Paclitaxel, Carboplatin NCT04623775 COMPLETED A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) 2026-05-06
Brigatinib, Tyrosine kinase inhibitor NCT04318938 COMPLETED Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients 2026-05-30
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Lazertinib-matching placebo 240 mg/160 mg, Gefitinib 250 mg, Gefitinib-matching placebo 250 mg, Lazertinib 240 mg/160 mg NCT04248829 COMPLETED A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer 2026-04-22
Crizotinib, Alectinib NCT02838420 COMPLETED Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer 2026-05-11
SY-5007 NCT06031558 ACTIVE_NOT_RECRUITING A Phase III, Open-Label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC. 2026-06-20
Paclitaxel + carboplatin, Durvalumab (MEDI4736), Pemetrexed + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Gemcitabine + cisplatin NCT03003962 ACTIVE_NOT_RECRUITING A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer 2026-06-30
Avelumab NCT03815643 ACTIVE_NOT_RECRUITING An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies 2026-08-21
Vilanterol and Umeclidinium Bromide NCT04536675 ACTIVE_NOT_RECRUITING Effect of Perioperative Fixed-dose Dual Bronchodilator Therapy on Post-operative Pulmonary Function Among Mild- to -Moderate COPD Patients Undergoing Lung Cancer Surgery 2026-09
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.